EP4247401A4 - COMPOSITIONS AND METHODS FOR OPTIMIZED PEPTIDE VACCINES - Google Patents

COMPOSITIONS AND METHODS FOR OPTIMIZED PEPTIDE VACCINES

Info

Publication number
EP4247401A4
EP4247401A4 EP21895640.7A EP21895640A EP4247401A4 EP 4247401 A4 EP4247401 A4 EP 4247401A4 EP 21895640 A EP21895640 A EP 21895640A EP 4247401 A4 EP4247401 A4 EP 4247401A4
Authority
EP
European Patent Office
Prior art keywords
compositions
methods
peptide vaccines
optimized peptide
optimized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21895640.7A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP4247401A1 (en
Inventor
David Gifford
Brandon CARTER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Think Therapeutics Inc
Original Assignee
Think Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/100,630 external-priority patent/US11058751B1/en
Priority claimed from US17/114,237 external-priority patent/US11161892B1/en
Priority claimed from US17/389,875 external-priority patent/US11421015B2/en
Application filed by Think Therapeutics Inc filed Critical Think Therapeutics Inc
Publication of EP4247401A1 publication Critical patent/EP4247401A1/en
Publication of EP4247401A4 publication Critical patent/EP4247401A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001164—GTPases, e.g. Ras or Rho
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/05—Hydrolases acting on acid anhydrides (3.6) acting on GTP; involved in cellular and subcellular movement (3.6.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP21895640.7A 2020-11-20 2021-11-19 COMPOSITIONS AND METHODS FOR OPTIMIZED PEPTIDE VACCINES Pending EP4247401A4 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US17/100,630 US11058751B1 (en) 2020-11-20 2020-11-20 Compositions for optimized RAS peptide vaccines
US17/114,237 US11161892B1 (en) 2020-12-07 2020-12-07 Method of compact peptide vaccines using residue optimization
US17/336,960 US11235039B1 (en) 2020-11-20 2021-06-02 Immunogenic compositions comprising nucleic acids for RAS peptides
US17/389,875 US11421015B2 (en) 2020-12-07 2021-07-30 Method of compact peptide vaccines using residue optimization
US202163249235P 2021-09-28 2021-09-28
PCT/US2021/060013 WO2022109220A1 (en) 2020-11-20 2021-11-19 Compositions and methods for optimized peptide vaccines

Publications (2)

Publication Number Publication Date
EP4247401A1 EP4247401A1 (en) 2023-09-27
EP4247401A4 true EP4247401A4 (en) 2025-06-11

Family

ID=81708071

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21895640.7A Pending EP4247401A4 (en) 2020-11-20 2021-11-19 COMPOSITIONS AND METHODS FOR OPTIMIZED PEPTIDE VACCINES

Country Status (5)

Country Link
EP (1) EP4247401A4 (enExample)
JP (1) JP7829242B2 (enExample)
AU (1) AU2021381384A1 (enExample)
CA (1) CA3202227A1 (enExample)
WO (1) WO2022109220A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240131133A1 (en) * 2022-10-10 2024-04-25 Think Therapeutics, Inc. Compositions and methods for optimized kras peptide vaccines
CN116130005B (zh) * 2023-01-30 2023-06-16 深圳新合睿恩生物医疗科技有限公司 多表位疫苗的串联设计方法及装置、设备、存储介质

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013177214A2 (en) * 2012-05-21 2013-11-28 Distributed Bio Inc Epitope focusing by variable effective antigen surface concentration
WO2018081459A1 (en) * 2016-10-26 2018-05-03 Modernatx, Inc. Messenger ribonucleic acids for enhancing immune responses and methods of use thereof
WO2020123300A2 (en) * 2018-12-14 2020-06-18 Eli Lilly And Company Kras variant mrna molecules
US11161892B1 (en) * 2020-12-07 2021-11-02 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016154047A2 (en) * 2015-03-20 2016-09-29 Memorial Sloan-Kettering Cancer Center Monoclonal antigen-binding proteins to intracellular oncogene products
RU2719033C2 (ru) * 2015-04-23 2020-04-16 Нантомикс, Ллс Способ получения фармацевтического агента для иммунотерапии рака
EP3294324A1 (en) * 2015-05-13 2018-03-21 Agenus Inc. Vaccines for treatment and prevention of cancer
CA2986235A1 (en) * 2015-05-20 2016-11-24 The Broad Institute, Inc. Shared neoantigens
EP4159751A1 (en) 2016-08-02 2023-04-05 The United States of America, as represented by the Secretary, Department of Health and Human Services Anti-kras-g12d t cell receptors
EP3576780A1 (en) 2017-02-01 2019-12-11 Modernatx, Inc. Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
EP3576764A4 (en) 2017-02-03 2020-12-16 The Medical College of Wisconsin, Inc. KRAS PEPTIDIC VACCINE COMPOSITIONS AND METHOD OF USE
CN108395479B (zh) 2017-02-06 2021-07-16 高军 一种有关kras基因突变的t细胞受体
WO2019246286A1 (en) * 2018-06-19 2019-12-26 Neon Therapeutics, Inc. Neoantigens and uses thereof
WO2020210202A1 (en) 2019-04-11 2020-10-15 The Board Of Trustees Of The Leland Stanford Junior University Cytotoxic t lymphocytes specific for mutated forms of epidermal growth factor receptor for use in treating cancer
US11058751B1 (en) * 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013177214A2 (en) * 2012-05-21 2013-11-28 Distributed Bio Inc Epitope focusing by variable effective antigen surface concentration
WO2018081459A1 (en) * 2016-10-26 2018-05-03 Modernatx, Inc. Messenger ribonucleic acids for enhancing immune responses and methods of use thereof
WO2020123300A2 (en) * 2018-12-14 2020-06-18 Eli Lilly And Company Kras variant mrna molecules
US11161892B1 (en) * 2020-12-07 2021-11-02 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2022109220A1 *

Also Published As

Publication number Publication date
AU2021381384A1 (en) 2023-06-22
EP4247401A1 (en) 2023-09-27
JP7829242B2 (ja) 2026-03-13
WO2022109220A1 (en) 2022-05-27
JP2023551204A (ja) 2023-12-07
CA3202227A1 (en) 2022-05-27

Similar Documents

Publication Publication Date Title
EP4110383A4 (en) COMPOSITIONS AND METHODS FOR MUCOSAL VACCINATION AGAINST SARS-COV-2
AU2022344251A1 (en) Serpina-modulating compositions and methods
AU2022342169A1 (en) Hbb-modulating compositions and methods
EP3894571A4 (en) COMPOSITIONS AND METHODS FOR BYPASSING HUMORAL IMMUNITY
AU2022342168A1 (en) Pah-modulating compositions and methods
CA3263582A1 (en) COMPOSITIONS AND METHODS FOR INDUCING FERROPTOSE
IL320789A (en) Preparations and methods for protein internalization
EP4140501A4 (en) IMPROVED PEPTIDE VACCINE
EP4162058A4 (en) COMPOSITIONS AND METHODS FOR ENHANCING THE IMMUNE RESPONSE
EP4247402A4 (en) METHODS AND COMPOSITIONS COMPRISING MHC CLASS I PEPTIDES
EP3866830A4 (en) VACCINE-POLYPEPTIDE COMPOSITIONS AND METHODS
EP4288062A4 (en) FOSPROPOFOL METHODS AND COMPOSITIONS
AU2020902546A0 (en) Vaccination methods and compositions
HK40116337A (en) Peptide vaccine
AU2019902942A0 (en) Vaccination methods and compositions
AU2021901273A0 (en) Combination methods for immunotherapy and related compositions
HK40125983A (en) Compositions and methods for protein internalization
CA3304052A1 (en) Vaccine compositions and uses thereof
AU2020901395A0 (en) Combination methods for immunotherapy and related compositions
HK40082815A (en) Peptide conjugates and methods of use
HK40066116A (en) Gene-regulating compositions and methods for improved immunotherapy
HK40066588A (en) Optimized vaccine compositions and methods for making the same
HK40117236A (en) Compositions and methods comprising anti-nrp2a antibodies
AU2023902828A0 (en) Flavivirus vaccine compositions and related methods
HK40104694A (en) Compositions and methods for anti-pacap antibodies

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230620

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0038000000

Ipc: A61K0039000000

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/62 20060101ALI20250214BHEP

Ipc: C07K 19/00 20060101ALI20250214BHEP

Ipc: C07K 7/06 20060101ALI20250214BHEP

Ipc: C07K 7/04 20060101ALI20250214BHEP

Ipc: A61K 38/08 20190101ALI20250214BHEP

Ipc: A61K 39/00 20060101AFI20250214BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20250514

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/62 20060101ALI20250508BHEP

Ipc: C07K 19/00 20060101ALI20250508BHEP

Ipc: C07K 7/06 20060101ALI20250508BHEP

Ipc: C07K 7/04 20060101ALI20250508BHEP

Ipc: A61K 38/08 20190101ALI20250508BHEP

Ipc: A61K 39/00 20060101AFI20250508BHEP